BOSTON -- A consortium of the EU pharma companies launched an open access journal titled "Drug Discovery International" (http://www.drugdiscovery.ch/ (http://www.drugdiscovery.ch/)). For three years the major purpose of this journal was to help popularize research presented at the largest EU drug discovery conference, MipTec (http://www.miptec.ch/ (http://www.facebook.com/l.php?u=http%3A%2F%2Fwww.miptec.ch%2F&h=oAQFZXIFX&enc=AZPgTszXWF-srown3laDolVCA8K1Rc7SAnKhv2EMC1KJI747UaAS1w8gl7HApPL-thf7i7PkBBCOSI5cDL9N7vBy6KYdg2nWrGmTNaGyKQ82ITaoGcvJ_N7tEEdkkpoN62I&s=1)). Recently they got the resources to expand the journal's reach.

Thanks to one of the early evangelists of aging research within the large pharma, Dr. Bhupinder Bhullar at Novartis, the first issue of Drug Discovery will be focused on aging research. The deadline for submission is 1st of March.

Even though the journal does not have an impact factor, it has a unique promoter base comprised of the scientists and executives of large pharma.
This may be a good chance to feature your research to the many large pharmaceutical companies like Novartis, Roche, Actelion, AZN, Boehringer-Ingelheim, GSK and many others.

Also, MipTec just confirmed that they will be adding the Aging Forum (called World Symposium on Geroprotectors: Aging Research for Drug Discovery) in Basel, Switzerland (Sept 23-24) and the event will be Free to attend. The scientific program is being finalized, please keep in touch (http://www.miptec.ch/miptec2014/scientific-program/scient... ). Last year the event was attended by over 3,000 people.


Contact
Gneteeva